THERAPY DOSSIER · th-9b01e03a7df2

Cyanidin-3-O-glucoside, free and encapsulated in chitosan-tripolyphosphate nanoparticles (Nano-C3G)

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29732888 ↗2018Reported benefit

Nanoencapsulation of Cyanidin-3-O-glucoside Enhances Protection Against UVB-Induced Epidermal Damage through Regulation of p53-Mediated Apoptosis in Mice.

MouseRadiationKunming (KM)femaleTopical application to dorsal skinNano-C3G at 125, 250 and 500 micromolar; free C3G at 500 mi…Applied after dehairing and before or around UVB exposure (stated as treated af…

Model: Acute skin photodamage induced by exposing dehaired dorsal skin to 2 J/cm2 of UVB

Nano-C3G reduced UVB-induced lipid peroxidation, malondialdehyde and 8-hydroxy-2'-deoxyguanosine, downregulated p53, Bax and caspases 3 and 9, and improved skin appearance, moisture, histology and apoptotic index. Nano-C3G was more effective than free C3G at the same 500 micromolar concentration.

Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…